NCT02689453 2022-04-29Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)National Institutes of Health Clinical Center (CC)Phase 1 Completed11 enrolled 16 charts